From Zacks Investment Research: 2025-01-17 16:08:08

J&J will acquire Intra-Cellular Therapies for $14.6 billion, adding Caplyta to its neuroscience pipeline. Eli Lilly announced disappointing Q4 sales numbers and lowered investor guidance. Pfizer’s bladder cancer drug study met a critical milestone. AstraZeneca and Daiichi Sankyo’s lung cancer drug received FDA priority review. AbbVie struck a deal for a multiple myeloma drug with a Chinese biotech. In other news, Lilly acquired Scorpion Therapeutics’ PI3Kα inhibitor, Pfizer’s PD-1 inhibitor study showed positive results, and J&J submitted an NDA for a bladder cancer drug. Stocks like J&J rose, while Lilly declined in the last five trading sessions. Next week, watch for J&J’s Q4 earnings and industry updates.



Read more at Zacks Investment Research: Pharma Stock Roundup: J&J’s ITCI Buyout, LLY’s Weak Q4 Sales – January 17, 2025